INCYTE
Incyte 2014 Annual Report
to Stockholders
Jakafi® (ruxolitinib)
Prescribing Information

is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs, primarily for oncology.

News
Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis
Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings
Incyte Reports 2015 First-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
Jakafi® (ruxolitinib)
IncyteCARES
Connecting to Access, Reimbursement, Education and Support
To learn more, click here